FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
    • Publication highlights
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Links
  • Events
    • Guest lectures
    • Retreats
    • Symposium
  • News
✕

New book with an angle on how patients can profit from inflammatory eye disease research

Cooperation between specialists is clearly crucial for gaining excellent results in the laboratory, and without these, there is no foundation for meaningful change in patient care. However, a deep and connected understanding of all the entities involved and the ability to communicate this understanding are also crucial in the process of translating research results into improvements in the treatment of patients in clinical settings.

In the research unit FOR 2240, principle investigators from Project 1 “Induction of transplant tolerance by antihem- and antilymphangiogenic therapies” and Project 8 “The role of interleukin (IL)-10 in the pathogenesis of autoimmune uveitis in mice and man” have written a new book together in which major elements of the topic “Inflammatory Eye Diseases” are clearly explained, and which also shows how advances in research involving these diseases translates into improvement of patient care.

The authors, Claus Cursiefen (Principle Investigator, P1) and Arnd Heiligenhaus (Principle Investigator, P8), are both intensely devoted to translational aims in their careers. Prof. Heiligenhaus is the Head of the Dept. of Ophthalmology at St. Franziskus Hospital in Muenster, Germany, and Prof. Cursiefen is the Chairman of the Dept. of Ophthalmology and University Eye Hospital in Cologne, Germany.

The book, with the German title “Entzündliche Augenerkrankungen” (Inflammatory Eye Diseases), is scheduled to appear on 25 May 2016. It will be published in the Series “Schlaglicht Augenheilkunde” (Spotlight Ophthalmology), edited by Gerhard K. Lang and Gabriele E. Lang, by Thieme in Stuttgart, Germany.

One example with a translational angle that Prof. Cursiefen and Prof. Heiligenhaus put forward is the immunomodulatory therapy needed to prevent graft rejections after two different kinds of corneal transplants (full-thickness and lamellar). This a major clinical focus of the Eye Clinic at the University of Cologne and also of the FOR 2240. This complements the general aim of providing a view of the state-of-the-art in the diagnosis and therapy of inflammatory diseases of the eye, which are the clinical foci of Prof. Heiligenhaus’s department in Muenster.

Related posts

January 7, 2023

Dr. Sarah Barbara Zwingelberg, is awarded Belmonte Fellowship for research on the neurobiology of the ocular surface


Read more
December 15, 2022

Leonhard Klein-Preis for Prof. Matthaei


Read more
November 22, 2022

4th Shanghai-Cologne Scientific Symposium


Read more

News

  • Rare eye diseases: Eight million euros for research: Funding for four years
  • Dr. Sarah Barbara Zwingelberg, is awarded Belmonte Fellowship for research on the neurobiology of the ocular surface
  • Experimental Glaucoma Research Group awarded and funded
  • Leonhard Klein-Preis for Prof. Matthaei
  • 4th Shanghai-Cologne Scientific Symposium

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Esther Engel
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
esther.engel@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck